KHTRF Stock - Knight Therapeutics Inc.
Unlock GoAI Insights for KHTRF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $371.30M | $328.20M | $293.56M | $243.48M | $199.52M |
| Gross Profit | $174.41M | $152.65M | $138.06M | $115.41M | $81.69M |
| Gross Margin | 47.0% | 46.5% | 47.0% | 47.4% | 40.9% |
| Operating Income | $7.40M | $-2,890,000 | $-2,403,000 | $-5,322,000 | $-3,437,000 |
| Net Income | $4.33M | $-16,835,000 | $-29,892,000 | $15.68M | $31.76M |
| Net Margin | 1.2% | -5.1% | -10.2% | 6.4% | 15.9% |
| EPS | $0.04 | $-0.16 | $-0.26 | $0.13 | $0.24 |
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
Visit WebsiteEarnings History & Surprises
KHTRFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.01 | $-0.02 | -280.9% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $0.01 | $-0.09 | -780.2% | ✗ MISS |
Q2 2025 | May 8, 2025 | $0.00 | $0.02 | +306.6% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $0.01 | $0.07 | +492.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.01 | $0.00 | -95.2% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $0.02 | $-0.01 | -181.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.01 | $-0.03 | -457.0% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.01 | $-0.18 | -1957.3% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.02 | $0.07 | +378.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.01 | $0.01 | +348.6% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.03 | $-0.03 | +21.8% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.08 | $-0.13 | -62.5% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $0.00 | $0.01 | +122.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $0.01 | $0.02 | +191.1% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.04 | $-0.16 | -300.0% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.00 | $-0.07 | -3400.0% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.01 | $-0.07 | -511.9% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-0.07 | $0.23 | +428.6% | ✓ BEAT |
Latest News
Profound Medical Regains Exclusive Distribution Rights For TULSA-PRO From Knight Therapeutics In Canada
📈 PositiveKnight Therapeutics Raises FY2025 Sales Guidance from $410.000M-$420.000M to $430.000M-$440.000M vs $415.092M Est
📈 PositiveKnight Therapeutics Q3 EPS $(0.04) Misses $(0.00) Estimate, Sales $121.548M Beat $106.979M Estimate
➖ NeutralFrequently Asked Questions about KHTRF
What is KHTRF's current stock price?
What is the analyst price target for KHTRF?
What sector is Knight Therapeutics Inc. in?
What is KHTRF's market cap?
Does KHTRF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to KHTRF for comparison